









Markets
/
Stocks
/
nasdaq-avxl
/

Anavex Life Sciences Corp

AVXL

4.100USD

+0.290+7.61%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

355.34MMarket Cap

LossP/E TTM



Anavex Life Sciences Corp

4.100

+0.290+7.61%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Anavex Life Sciences Corp

Currency: USD Updated: 2026-02-06

Key Insights

Anavex Life Sciences Corp's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 160 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 22.00.In the medium term, the stock price is expected to trend down.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Anavex Life Sciences Corp's Score

Industry at a Glance

Industry Ranking

160 / 392

Overall Ranking

307 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

Anavex Life Sciences Corp Highlights

StrengthsRisks

Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system (CNS) diseases with high unmet need. The Company analyzes genomic data from clinical trials to identify biomarkers, which it uses in the analysis of its clinical trials. Its focus is on developing treatments for Alzheimer’s disease, Parkinson’s disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other CNS disorders. It has two core programs and two seed programs. ANAVEX 2-73 is being developed as an oral liquid once-daily formulation for rare diseases such as Rett syndrome as well as an oral once-daily capsule formulation for diseases such as Alzheimer’s disease. ANAVEX 3-71 is a CNS-penetrable potential disease-modifying treatment for cognitive impairments. Its other candidates include ANAVEX 1-41, ANAVEX 1066 and ANAVEX 1037.

Overvalued

The company’s latest PE is -7.54, at a high 3-year percentile range.

Institutional Buying

The latest institutional holdings are 33.18M shares, increasing 0.05% quarter-over-quarter.

Held by PRFDX

Star Investor PRFDX holds 8.13K shares of this stock.

Analyst Rating

Based on 3 analysts

Buy

Current Rating

22.000

Target Price

+477.43%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Anavex Life Sciences Corp is 6.91, ranking 187 out of 392 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

6.91

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

6.78

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

4.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.03

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Anavex Life Sciences Corp's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Anavex Life Sciences Corp is 6.87, ranking 208 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -7.54, which is -27.93% below the recent high of -5.43 and -223.33% above the recent low of -24.38.

Score

Industry at a Glance

Previous score

6.87

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 160/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Anavex Life Sciences Corp is 7.33, ranking 294 out of 392 in the Biotechnology & Medical Research industry. The average price target is 22.00, with a high of 24.00 and a low of 20.00.

Score

Industry at a Glance

Previous score

7.33

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 3 analysts

Buy

Current Rating

22.000

Target Price

+477.43%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

Anavex Life Sciences Corp

AVXL

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Beigene Ltd

ONC

Intellia Therapeutics Inc

NTLA

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Anavex Life Sciences Corp is 6.65, ranking 204 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 5.04 and the support level at 3.49, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.32

Change

0.33

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(2)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.255

Neutral

RSI(14)

40.322

Neutral

STOCH(KDJ)(9,3,3)

12.985

Oversold

ATR(14)

0.305

Low Volatility

CCI(14)

-127.943

Sell

Williams %R

81.290

Oversold

TRIX(12,20)

0.301

Sell

StochRSI(14)

60.194

Buy

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

4.190

Sell

MA10

4.550

Sell

MA20

4.714

Sell

MA50

4.256

Sell

MA100

6.016

Sell

MA200

7.779

Sell

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Anavex Life Sciences Corp is 3.00, ranking 197 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 40.32%, representing a quarter-over-quarter decrease of 4.59%. The largest institutional shareholder is The Vanguard, holding a total of 5.01M shares, representing 5.61% of shares outstanding, with 1.98% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

BlackRock Institutional Trust Company, N.A.

6.33M

+1.84%

The Vanguard Group, Inc.

Star Investors

5.09M

-0.05%

State Street Investment Management (US)

3.29M

+11.47%

Geode Capital Management, L.L.C.

2.03M

+0.37%

Two Sigma Investments, LP

1.80M

-0.07%

Missling (Christopher U)

1.51M

Skarpelos (Athanasios)

1.31M

Northwest Asset Management

874.28K

-14.66%

Charles Schwab Investment Management, Inc.

717.38K

+1.09%

Northern Trust Investments, Inc.

695.29K

-2.76%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. No risk assessment score is currently available for Anavex Life Sciences Corp. The Biotechnology & Medical Research industry's average is 3.38. The company's beta value is 1.10. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.